This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lang, I. M. Articles by Schleef, R. R. Search for Related Content PubMed PubMed Citation Articles by Lang, I. M. Articles by Schleef, R. R.

Circulation, Vol 90, 706-712, Copyright © 1994 by American Heart Association

ARTICLES

Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli

IM Lang, JJ Marsh, MA Olman, KM Moser and RR Schleef
Division of Pulmonary and Critical Care Medicine, University of California San Diego.

BACKGROUND: Chronic thromboembolic pulmonary hypertension is the result of nonresolving pulmonary emboli that lead to chronic obstruction of the central pulmonary arteries. METHODS AND RESULTS: To determine if the failure to lyse pulmonary thromboemboli is caused by an abnormality in the endothelial cell (EC)-associated fibrinolytic system, conditions were established to culture ECs from patient main pulmonary arteries during surgical pulmonary thromboendarterectomies and to analyze the conditioned media for levels of tissue-type plasminogen activator (TPA) and type 1 plasminogen activator inhibitor (PAI-1). Our data indicate that the levels of TPA antigen and PAI-1 activity in media conditioned by primary ECs harvested from areas free of thrombus were not significantly different between patients with chronic thromboemboli and organ donors. In 13 consecutive patients, no correlation was obtained in either the TPA antigen or PAI-1 activity level in a patient's plasma and the respective levels in media conditioned by the patient's pulmonary ECs. Moreover, patient pulmonary arterial ECs were observed to increase the secretion of TPA and PAI-1 in response to thrombin in a fashion similar to donor pulmonary artery ECs. CONCLUSIONS: The data suggest that an inherent EC-mediated fibrinolytic imbalance is not a generalized phenomenon observed in pulmonary arteries of patients with chronic pulmonary thromboemboli.

This article has been cited by other articles:

				A. L. Firth, J. Yau, A. White, P. G. Chiles, J. J. Marsh, T. A. Morris, and J. X.-J. Yuan Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells Am J Physiol Lung Cell Mol Physiol, June 1, 2009; 296(6): L979 - L986. [Abstract] [Full Text] [PDF]

				I. M. Lang Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Eur. Respir. Rev., March 1, 2009; 18(111): 24 - 28. [Abstract] [Full Text] [PDF]

				D. Bonderman, J. Jakowitsch, B. Redwan, H. Bergmeister, M.-K. Renner, H. Panzenbock, C. Adlbrecht, A. Georgopoulos, W. Klepetko, M. Kneussl, et al. Role for Staphylococci in Misguided Thrombus Resolution of Chronic Thromboembolic Pulmonary Hypertension Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 678 - 684. [Abstract] [Full Text] [PDF]

				K. McNeil and J. Dunning Chronic thromboembolic pulmonary hypertension (CTEPH) Heart, September 1, 2007; 93(9): 1152 - 1158. [Full Text] [PDF]

				N. Galie and N. H. S. Kim Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension Proceedings of the ATS, September 1, 2006; 3(7): 571 - 576. [Abstract] [Full Text] [PDF]

				A. Peacock, G. Simonneau, and L. Rubin Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension Proceedings of the ATS, September 1, 2006; 3(7): 608 - 614. [Abstract] [Full Text] [PDF]

				T. A. Morris, J. J. Marsh, P. G. Chiles, W. R. Auger, P. F. Fedullo, and V. L. Woods Jr. Fibrin Derived from Patients with Chronic Thromboembolic Pulmonary Hypertension Is Resistant to Lysis Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1270 - 1275. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, E. Mayer, G. Simonneau, and L. J. Rubin Chronic Thromboembolic Pulmonary Hypertension Circulation, April 25, 2006; 113(16): 2011 - 2020. [Full Text] [PDF]

				X Jais, V Ioos, C Jardim, O Sitbon, F Parent, A Hamid, E Fadel, P Dartevelle, G Simonneau, and M Humbert Splenectomy and chronic thromboembolic pulmonary hypertension Thorax, December 1, 2005; 60(12): 1031 - 1034. [Abstract] [Full Text] [PDF]

				F. Sakamaki, S. Kyotani, N. Nagaya, N. Sato, H. Oya, and N. Nakanishi Increase in Thrombomodulin Concentrations After Pulmonary Thromboendarterectomy in Chronic Thromboembolic Pulmonary Hypertension Chest, October 1, 2003; 124(4): 1305 - 1311. [Abstract] [Full Text] [PDF]

				P. Prabhakaran, L. B. Ware, K. E. White, M. T. Cross, M. A. Matthay, and M. A. Olman Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L20 - L28. [Abstract] [Full Text] [PDF]

				K. Laczika, I. M. Lang, P. Quehenberger, C. Mannhalter, M. Muhm, W. Klepetko, and P. A. Kyrle Unilateral Chronic Thromboembolic Pulmonary Disease Associated With Combined Inherited Thrombophilia Chest, January 1, 2002; 121(1): 286 - 289. [Abstract] [Full Text] [PDF]

				P. F. Fedullo, W. R. Auger, K. M. Kerr, and L. J. Rubin Chronic Thromboembolic Pulmonary Hypertension N. Engl. J. Med., November 15, 2001; 345(20): 1465 - 1472. [Full Text] [PDF]

				W. L. Simmons, K. E. Rivera, D. T. Curiel, W. F. Williams, and M. A. Olman Adenovirally Mediated Gene Transfer of Functional Human Tissue-type Plasminogen Activator to Murine Lungs Am. J. Respir. Cell Mol. Biol., March 1, 1998; 18(3): 307 - 314. [Abstract] [Full Text]